Disclaimer. LEGAL AND POLICY CONSIDERATIONS OF NALOXONE FOR OPIOID TOXICITY REVERSAL.

Slides:

Advertisements

Similar presentations

The Take Home Naloxone Program in British Columbia, Canada Erin Gibson, Despina Tzemis, Jane Buxton BC Centre for Disease Control Harm Reduction Program.

Advertisements

Strategies for Incorporating OD Prevention Into Your Work Eliza Wheeler Drug Overdose Prevention & Education (DOPE) Project Harm Reduction Coalition

Naloxone: Cost, Logistics, and Supply Issues Community Pharmacy Perspective Krystalyn Weaver, PharmD National Alliance of State Pharmacy Associations.

Back to School 2013: An Immunization Checklist

Talking to Patients About HCV Treatment

RISK RECOGNITION IN HEALTHCARE SETTINGS

Optimizing Statin Therapy

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

NOACs In Long-term VTE Treatment: A State Of The Art Review

Statin Selection Aimed to Reduce New-Onset DM Risk:

Optimizing Therapy for Osteoarthritis

Heart Rate, HF Admissions, and Readmissions

Expert Perspectives on Clinically Challenging Cases in Narcolepsy

Differentiating Drug-Seeking Behavior From Poorly Controlled Pain

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

The Cancer Pain Journey: Optimizing Identification and Management

Pulmonary Embolism Scope of the Problem Massive vs Submassive Pulmonary Embolism.

Oral Anticoagulants in AFa,b A Brief History.

Managing IBD in Children

Assessment and Management of Acute Pain: A Focus on the Role of Opioids and Multimodal Treatment Approaches.

Clinical Considerations in Evidence-based Management of GIST

Lessons Learned In Opioid Treatment From the Pain Action Consulting Team.

Opioids in Butte County

Counseling Patients About Germline BRCA Mutations

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

Introduction. Family Planning and Pregnancy Management in Patients With Chronic Inflammatory Rheumatic Diseases.

Improving Management of Type 2 Diabetes in Hispanic/Latino Patients

Are We Closer to Personalized Medicine in MS?

A Frontline Clinician's Guide to Managing Opioid-Induced Constipation

Seizures in the Elderly: Treatment and Special Considerations

From Symptom Management to Communication in Advanced GI Cancers

Practical Guidance on Using New Therapies for Relapsed/ Refractory Follicular Lymphoma and Chronic Lymphocytic Leukemia.

Avoiding Opioid Overuse: Guideline-Based Management of Osteoarthritis

Improving Appropriate Access to PCSK9 Inhibitors

Charting Progress in MS Treatment:

Poor Response to Initial Therapy for Migraine

Improving Therapeutic Management of Huntington's Disease in Long-Term Care.

An Interprofessional Perspective on the Safe and Appropriate Use of Opioid Analgesics.

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

What's New on Interventions for Lower Limb Spasticity?

Combining Efforts for Older Drivers: Licensing Agencies, Occupational Therapists, and Clinicians.

Program Goals Overview Is NEDA a Reasonable Target?

Novel Insulin/GLP-1 Combinations: Of Interest to the Primary Care Physician?

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Considerations in Managing Seizures in Women

Program Goals Disclaimers Defining Refractory Seizures.

Pharmacists’ role in opioid overdose: Kentucky pharmacists’ willingness to participate in naloxone dispensing Patricia R. Freeman, Amie Goodin, SuZanne.

Insulin in Diabetes Management: Effective Patient Selection Is Key

Application of Biologics in IBD:

Jonathan Penm, Neil J. MacKinnon, Jill M

Incorporating Prostacyclins Into Practice

Improving Adherence to Antiplatelet Therapy After an ACS Event

Clinical Challenges and Updates in Managing Seizure Clusters

Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.

Program Goal. Program Goal Disclaimer Overview.

A Family Affair.

Managing Pain in the 21st Century

Program Goals Overview Is NEDA a Reasonable Target?

Transitioning Therapy in PAH: Practical Strategies and Considerations

Clinical Considerations in Evidence-based Management of GIST

Incorporating New PAH Treatments Into Clinical Practice

A Pharmacist's Guide to Safety and Use of Immune Checkpoint Inhibitors

Championing Evidence-Based Care in Patients With Acute Low Back Pain

Mitigating Side Effects and Optimizing Compliance With Oral Therapies in CLL.

Practical Strategies for Overcoming Emotional Barriers to Insulin Initiation in the Primary Care Setting.

What's New in PAH?.

Fixed-Ratio Combination Therapy in T2DM

Ask the Psoriasis Expert

Care Team Collaboration for CAR T-Cell Therapy: Real-World Advice

Multimodal Approaches to Cracking the Code in Low Back Pain

Presentation transcript:

LEGAL AND POLICY CONSIDERATIONS OF NALOXONE FOR OPIOID TOXICITY REVERSAL

Disclaimer

Program Goals

Opioid as Part of Multimodal Strategy

Best Practices For Prescribing Chronic Opioid Therapy

Recent Legal Changes With Naloxone Use

Risk Factors for Opioid Overdose

Naloxone

Barriers to Naloxone Use

Current Legal/Policy Environment

Current Legal/Policy Environment (cont)

Current Legal/Policy Environment (cont)

Current Legal/Policy Environment (cont)

Recent Legal Changes With Naloxone Prescribing/Administration

Recent Legal Changes With Naloxone Prescribing/Administration (cont)

Lowering the Risk in Prescribing Chronic Opioid Therapy

Key Messages

Key Messages (cont)

Abbreviations

References

References (cont)

References (cont)